Novel Treatment Approaches in Recurrent/Metastatic Squamous Head and Neck Cancer
Authors:
- 3 October 2025
- journal article
- review article
- Published by Elsevier in Otolaryngologic Clinics of North America
- Vol. 59 (1) , 211-224
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Royal Marsden NHS Foundation Trust
- Pfizer
This publication has 64 references indexed in Scilit:
- 879P VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)Annals of Oncology, 2024
- Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectivesCancer Treatment Reviews, 2024
- 854O INTERLINK-1: Phase III study of cetuximab (CTX) ± monalizumab (M) in participants (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) with disease progression on/after platinum chemotherapy (CT) and previously treated with an immune checkpoint inhibitor (ICI)Annals of Oncology, 2023
- Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III studyAnnals of Oncology, 2022
- Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical ApplicationsClinical Lung Cancer, 2022
- Evaluation of Safety of Treatment With Anti–Epidermal Growth Factor Receptor Antibody Drug Conjugate MRG003 in Patients With Advanced Solid TumorsJAMA Oncology, 2022
- Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyAnnals of Oncology, 2020
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related CancerJAMA Oncology, 2019
- Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCCJAMA Oncology, 2018
- Phase 1 study of EGFR‐antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlativesCancer, 2018